Announcements
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study
1. Date of occurrence of the event: May 6, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned
1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company’s Board of Directors resolved to convene the 2021 Annual General Shareholders’ Meeting
1. Date of the board of directors’ resolution: April 29, 2021 2. General shareholders’ meeting date: June 15, 2021 3. General shareholders’ meeting location: 5th Floor, No.19, Shengyi 5th Rd., …
Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.
1. Date of the board of directors’ resolution: April 29, 2021 2. Type and monetary amount of dividend distribution: N/A 3. Any other matters that need to be specified: None
OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned
1. Date of occurrence of the event: April 21, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru
1. Date of occurrence of the event: Apr 20, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina
1. Date of occurrence of the event: Apr 7, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
1. Date of occurrence of the event: Mar 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …
The Board of Directors resolved to hold 2021 Annual General Meeting
1. Date of the board of directors resolution: Mar 12, 2021 2. Date for convening the shareholders’ meeting: Jun 21, 2021 3. Location for convening the shareholders’ meeting: Masterlink Securities …
Announcement of not Distributing Dividends in 2020
1. Date of the board of directors resolution: Mar 12, 2021 2. Year or quarter which dividends belong to: Year of 2020 3. Period which dividends belong to: Jan 01, …